Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

391 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics.
Ruiz-Patiño A, Rodríguez J, Cardona AF, Ávila J, Archila P, Carranza H, Vargas C, Otero J, Arrieta O, Zatarain-Barrón L, Sotelo C, Ordoñez C, García-Robledo JE, Rojas L, Bermúdez M, Gámez T, Mayorga D, Corrales L, Martín C, Recondo G, Mas L, Samtani S, Ricaurte L, Malapelle U, Russo A, Barrón F, Santoyo N, Rolfo C, Rosell R; ONCOLGroup; CLICaP. Ruiz-Patiño A, et al. Among authors: rolfo c. Transl Oncol. 2022 Jan;15(1):101276. doi: 10.1016/j.tranon.2021.101276. Epub 2021 Nov 22. Transl Oncol. 2022. PMID: 34823093 Free PMC article.
Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
Reguart N, Rosell R, Cardenal F, Cardona AF, Isla D, Palmero R, Moran T, Rolfo C, Pallarès MC, Insa A, Carcereny E, Majem M, De Castro J, Queralt C, Molina MA, Taron M. Reguart N, et al. Among authors: rolfo c. Lung Cancer. 2014 May;84(2):161-7. doi: 10.1016/j.lungcan.2014.02.011. Epub 2014 Mar 2. Lung Cancer. 2014. PMID: 24636848 Clinical Trial.
Recent developments in the use of immunotherapy in non-small cell lung cancer.
Santarpia M, Giovannetti E, Rolfo C, Karachaliou N, González-Cao M, Altavilla G, Rosell R. Santarpia M, et al. Among authors: rolfo c. Expert Rev Respir Med. 2016 Jul;10(7):781-98. doi: 10.1080/17476348.2016.1182866. Epub 2016 May 13. Expert Rev Respir Med. 2016. PMID: 27148808 Review.
BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations.
Cardona AF, Rojas L, Wills B, Arrieta O, Carranza H, Vargas C, Otero J, Corrales-Rodriguez L, Martín C, Reguart N, Archila P, Rodríguez J, Cuello M, Ortíz C, Franco S, Rolfo C, Rosell R, on behalf of the CLICaP. Cardona AF, et al. Among authors: rolfo c. Oncotarget. 2016 Sep 19;7(42):68933-68942. doi: 10.18632/oncotarget.12112. Oncotarget. 2016. PMID: 27926478 Free PMC article.
Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.
Malapelle U, Sirera R, Jantus-Lewintre E, Reclusa P, Calabuig-Fariñas S, Blasco A, Pisapia P, Rolfo C, Camps C. Malapelle U, et al. Among authors: rolfo c. Expert Rev Mol Diagn. 2017 Mar;17(3):209-215. doi: 10.1080/14737159.2017.1288568. Epub 2017 Feb 9. Expert Rev Mol Diagn. 2017. PMID: 28129709 Review.
Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab.
Wills B, Cardona AF, Rojas L, Ruiz-Patiño A, Arrieta O, Reguart N, Carranza H, Vargas C, Otero J, Corrales L, Martín C, Cuello M, Pino LE, Rolfo C, Rosell R, Zatarain-Barrón ZL; Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). Wills B, et al. Among authors: rolfo c. Anticancer Res. 2017 Nov;37(11):6429-6436. doi: 10.21873/anticanres.12097. Anticancer Res. 2017. PMID: 29061829
391 results